The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.

ABSTRACT:

Background

Interventions to protect young infants against respiratory syncytial virus (RSV) are in advanced phases of development and are expected to be available in the foreseeable future. Gavi, the Vaccine Alliance, included maternal vaccines and infant monoclonal antibodies for RSV as part of the 2018 vaccine investment strategy (VIS) and decided to support these products subject to licensure, World Health Organization prequalification, Strategic Advisory Group of Experts recommendation, and meeting the financial assumptions used as the basis of the investment case. Impact estimates reported in this manuscript were used to inform the Gavi VIS.

Methods

We compared two independent vaccine impact models to evaluate a potential maternal RSV vaccine's impact on infant health i

SUBMITTER: Baral R 

PROVIDER: S-EPMC7342012 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature